國家衛生研究院 NHRI:Item 3990099045/2993
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 909805      Online Users : 865
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/2993


    Title: A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells
    Authors: Huang, TS;Lee, CC;Chao, Y;Shu, CH;Chen, LT;Chen, LL;Chen, MH;Yuan, CC;Whang-Peng, J
    Contributors: National Institute of Cancer Research
    Abstract: Purpose. GL331 is a new homolog of VP-16, and has demonstrated more efficacious anti-cancer activity in both the in vitro and in vivo lymphoma systems. To extensively explore GL331's clinical value, we furthermore evaluate the cytotoxicity and apoptosis-inducing activity of GL331 in several human cell lines from cancers that are not normally treated with VP-16. Methods. By MTT and clonogenic survival assays, the cytotoxicities of GL331 and VP-16 were evaluated in a variety of cell lines including nasopharyngeal, hepatocellular, gastric, colon, cervical, and neuroblastoma cancer types. Western blot analysis was performed to detect the MDR-1 level in these cell lines. By Annexin V-staining flow cytometry and detection of DNA ladders, the apoptosis-inducing activities of GL331 and VP-16 were also evaluated. Results. GL331 showed more efficacy than its congener VP-16 in killing cancer cells. The estimated ID50 of GL331 were 2.5 to 17-fold lower than those of VP-16. GL331 possessed more cell-killing activity even in MDR-1-overexpressing cell lines such as HCC36 and SW620. Its higher cytotoxicity could be attributed by the elevated ability to induce apoptotic cell death. Conclusion. GL331's overriding drug resistance and higher cancer cell-killing activity suggest its superiority in clinical cancer therapy.
    Keywords: Chemistry, Multidisciplinary;Pharmacology & Pharmacy
    Date: 1999-07
    Relation: Pharmaceutical Research. 1999 Jul;16(7):997-1002.
    Link to: http://dx.doi.org/10.1023/A:1018971313256
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0724-8741&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000081837700004
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0032784679
    Appears in Collections:[Jacqueline Whang-Peng(1996-2007)] Periodical Articles
    [Li-Tzong Chen] Periodical Articles
    [Tze-Sing Huang] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    000081837700004.pdf969KbAdobe PDF418View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback